Global Bispecific Antibodies for Cancer Market 2019-2023
SKU ID :TNV-14141962 | Published Date: 17-Apr-2019 | No. of pages: 117Description
TOC
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY TARGET
Market segmentation by target
Comparison by target
CD19/CD3 - Market size and forecast 2018-2023
CD30/CD16A - Market size and forecast 2018-2023
Market opportunity by target
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Market trends
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Amgen Inc.
Astella Pharma Inc.
Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
Merus
Regeneron Pharmaceuticals, Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Bispecific antibodies for cancer under development
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Customer landscape
Exhibit 19: Target - Market share 2018-2023 (%)
Exhibit 20: Comparison by target
Exhibit 21: CD19/CD3 - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: CD19/CD3 - Year-over-year growth 2019-2023 (%)
Exhibit 23: CD30/CD16A - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: CD30/CD16A - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by target
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Pipeline for bispecific antibodies for cancer treatment
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen Inc. - Vendor overview
Exhibit 46: Amgen Inc. - Product segments
Exhibit 47: Amgen Inc. - Organizational developments
Exhibit 48: Amgen Inc. - Geographic focus
Exhibit 49: Amgen Inc. - Key offerings
Exhibit 50: Astella Pharma Inc. - Vendor overview
Exhibit 51: Astella Pharma Inc. - Business segments
Exhibit 52: Astella Pharma Inc. - Organizational developments
Exhibit 53: Astella Pharma Inc. - Key offerings
Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview
Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings
Exhibit 56: Merus - Vendor overview
Exhibit 57: Merus - Product segments
Exhibit 58: Merus - Key offerings
Exhibit 59: Regeneron Pharmaceuticals, Inc. - Vendor overview
Exhibit 60: Regeneron Pharmaceuticals, Inc. - Business segments
Exhibit 61: Regeneron Pharmaceuticals, Inc. - Organizational developments
Exhibit 62: Regeneron Pharmaceuticals, Inc. - Key offerings
Exhibit 63: Validation techniques employed for market sizing
Tables & Figures
Companies
Amgen Inc.
Astella Pharma Inc.
Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
Merus
Regeneron Pharmaceuticals, Inc.
- PRICE
-
$2500$4000Buy Now